Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

 Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Shots:

  • GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21
  • The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches
  • The agreement includes the global rights to three established brands (Zinnat, Zinacef, and Fortum) in 100+ markets. Additionally, Sandoz plans to expand its integrated manufacturing site in Kundl with the manufacturing of Zinnat

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Law.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post